AHOD2131——一项比较标准疗法和免疫肿瘤疗法治疗新诊断的I期和II期经典霍奇金淋巴瘤儿童和成人的随机3期中期反应适应试验
Read moreAOST2032: VEFGR2/MET抑制剂Cabozantinib联合细胞毒化疗治疗新诊断骨肉瘤的可行性和随机2/3期研究
Read moreACNS2031 -硫代硫酸钠降低顺铂诱导的中等风险成神经管细胞瘤儿童耳毒性和降低低风险成神经管细胞瘤儿童治疗的3期研究
Read moreACNS1831 - Selumetinib (IND #77782)与卡铂/长春新碱治疗新诊断或未治疗的1型神经纤维瘤病(NF1)相关低级别胶质瘤(LGG)的3期研究
Read moreAPAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Read moreARST2032 -一项针对新诊断极低风险和低风险融合阴性横纹肌肉瘤患者的前瞻性3期研究
Read moreACNS1821 - Selinexor (KPT-330)和放射治疗新诊断的儿童弥漫性脑桥内胶质瘤(DIPG)和高级别胶质瘤(HGG)的1/2期试验
Read moreA Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAF v600E or IDH1 Mutations
Read moreAOST2031, 一项比较开放与胸腔镜治疗骨肉瘤患者肺转移的3期随机对照试验
Read moreACCL2031 - A Phase 3 Randomized, 安慰剂对照试验评估美金刚(IND# 149832)在原发性中枢神经系统肿瘤儿童颅脑放疗中的神经认知保护作用
Read moreACNS2021: A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & 椎管照射治疗中枢神经系统非生发性生殖细胞肿瘤
Read moreARST2031 - A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide, VINO-AC Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide VINO-Cpo vs Vincristine, Dactinomycin and Cyclophosphamide VAC plus VINO-Cpo Maintenance in Patients with High-Risk Rhabdomyosarcoma HR-RMS
Read moreANHL1931 A Randomized Phase 3 Trial of Nivolumab (NSC# 748726, IND# 125462)联合化疗免疫治疗新诊断的原发性纵隔b细胞淋巴瘤
Read moreACNS1833 -卡铂和长春新碱对塞鲁美替尼的3期随机非劣效性研究(NSC# 748727), IND# 77782)治疗与BRAFV600E突变或1型系统性神经纤维瘤病(NF)无关的新诊断或未治疗的低级别胶质瘤(LGG)!)
Read moreARST1921: A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014; IND#146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Read moreALTE11C2 -蒽环类药物和放射治疗后的健康影响(HEART):右唑嗪和预防蒽环类药物相关
Cardiomyopathy
Read moreAPEC14B1 - Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
Read moreAAML1531 - Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Read moreARST1431 - A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC#683864, IND#122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Read moreAGCT1531 - A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Read moreAPEC1621 - NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Read moreAALL1631 -费城染色体阳性急性淋巴细胞白血病(Ph+ALL)的国际3期试验，测试伊马替尼联合两种不同的细胞毒性化疗主干
Read moreACNS1422 - A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Read moreAHEP1531 - Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Read moreAGCT1532 -一项针对中低风险转移性生殖细胞肿瘤患者的加速与标准BEP化疗的随机3期试验
Read moreAREN1721 - A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. 单药阿西替尼或尼伏单抗治疗所有年龄组TFE/易位性肾细胞癌(tRCC
Read moreACNS1721 - A Phase 2 Study of Veliparib (ABT-888, IND#139199) and Local Irradiation, 其次是维持性韦利帕利和替莫唑胺用于新诊断的高级别胶质瘤(HGG)患者，无H3 K27M或BRAFV600E突变
Read moreANBL1821 -一项伊立替康/替莫唑胺/地努妥昔单抗加或不加依氟鸟氨酸(DFMO)的2期随机研究
141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Read moreAALL1731 - A Phase 3 Trial Investigating Blinatumomab (IND# 117467, nsc# 765986)联合化疗治疗新诊断的标准风险或唐氏综合征淋巴母细胞白血病(B-ALL)和局部b淋巴母细胞淋巴瘤(B-LLy)患者
Read moreS1826- A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Read moreACNS1723 -新诊断患者局部放疗后Dabrafenib (NSC#763760)与Trametinib (NSC#763093)的2期研究
BRAFv600 - Mutant High-Grade Glioma (HGG) (IND #145355)
Read moreAALL1732 - A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND# 133494, NSC# 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Read moreANBL1531 - 131I-Metaiodobenzylguanidine (131I-MIBG)或Crizotinib加入新诊断的高危神经母细胞瘤(NBL)儿童强化治疗的3期研究(IND# 134379)
Read moreADVL18P1 -一项评估Enasidenib在伴有异柠檬酸脱氢酶2 (IDH2)突变的复发/难治性急性髓性白血病(R/R- aml)患儿中的安全性和药代动力学的开放标签可行性研究
Read moreAAML1831——一项针对新发AML患者的3期随机试验，比较包括吉妥珠单抗Ozogamicin (GO)在内的标准治疗与含GO的CPX-351, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Read moreNational Registry of Pediatric Cancer Patients Diagnosed with COVID-19
Read moreE4412 - A Phase 1 Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin
Read moreALTE2031 - StepByStep:青少年和年轻成人儿童癌症幸存者中移动健康和社交媒体体育活动干预的随机试验
Read moreAALL1821 - A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
Read moreANBL19P1 - A Pilot Study of Dinutuximab, Sargramostim (GMCSF), 异维a酸联合伊立替康和替莫唑胺治疗高危神经母细胞瘤
Read moreAREN1921 -新诊断的弥漫性间变性肾母细胞瘤(DAWT)和复发的组织学有利的肾母细胞瘤(FHWT)的治疗
Read moreAALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#TBD) in
Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Read moreALTE07C1 - Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
Read moreALTE05N1 - Umbrella Long-Term Follow-Up Protocol
Read moreALTE03N1 - Key Adverse Events Following Childhood Cancer
Read moreAREN03B2 - Renal Tumors Classification, Biology and Banking Study
Read moreANBL00B1 - Neuroblastoma Biology Studies
Read more
